InMed Pharmaceuticals Inc.
INM
$2.76
$0.010.36%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.92M | 4.83M | 4.96M | 4.60M | 5.63M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.92M | 4.83M | 4.96M | 4.60M | 5.63M |
| Cost of Revenue | 3.33M | 3.12M | 3.39M | 3.50M | 3.42M |
| Gross Profit | 1.60M | 1.71M | 1.57M | 1.10M | 2.21M |
| SG&A Expenses | 5.52M | 5.56M | 5.37M | 5.25M | 5.45M |
| Depreciation & Amortization | 214.90K | 217.40K | 219.40K | 219.60K | 218.30K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.01M | 12.60M | 12.22M | 12.73M | 12.27M |
| Operating Income | -8.08M | -7.77M | -7.26M | -8.13M | -6.64M |
| Income Before Tax | -8.30M | -7.91M | -6.81M | -7.67M | -6.07M |
| Income Tax Expenses | 7.10K | 7.10K | 7.10K | 7.10K | 1.80K |
| Earnings from Continuing Operations | -8.31 | -7.91 | -6.82 | -7.68 | -6.08 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.31M | -7.91M | -6.82M | -7.68M | -6.08M |
| EBIT | -8.08M | -7.77M | -7.26M | -8.13M | -6.64M |
| EBITDA | -7.87M | -7.55M | -7.04M | -7.91M | -6.42M |
| EPS Basic | -12.32 | -13.97 | -14.04 | -26.57 | -24.57 |
| Normalized Basic EPS | -7.69 | -8.72 | -8.76 | -16.60 | -15.35 |
| EPS Diluted | -12.32 | -13.97 | -14.04 | -26.57 | -24.57 |
| Normalized Diluted EPS | -7.69 | -8.72 | -8.76 | -16.60 | -15.35 |
| Average Basic Shares Outstanding | 2.90M | 2.29M | 1.98M | 1.53M | 1.21M |
| Average Diluted Shares Outstanding | 2.90M | 2.29M | 1.98M | 1.53M | 1.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |